Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Wacker expands biologics with acquisition of ADL BioPharma
by Rick Mullin
May 18, 2023
| A version of this story appeared in
Volume 101, Issue 16
Wacker Chemie will spend about $100 million to acquire ADL BioPharma, a biologics firm in León, Spain. The German chemical group purchased fermentation assets at ADL’s site in 2016. The broader acquisition will expand its fermentation capacity by roughly 2,000 m3, as well as give it additional recovery and purification processes. Wacker says it will retain the staff of 300 at the company, which manufactures fermentation-based products for the food, pharmaceutical, and consumer good industries.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter